Non-TIGIT-targeting therapies, such as the anti-CTLA-4 antibody Cetuximab and the TLR8 agonist Motolimod, may also downregulate TIGIT expression in HNSCC [96]. Here, CTLA4 is linked to head and neck squamous cell carcinoma.